E-DRUG: Independent Drug Bulletin from Japan in English (Dec 2016)
------------------------------------------------------------------------------------
Dear E-drug colleagues
Japanese independent drug bulletin
"Med Check in English December 2016,e$B!!e(JVol.2, No.6
is uploaded.
http://www.npojip.org/english/MedCheck/medchecktip.html
http://www.npojip.org/english/MedCheck/Med%20Check-TIP%2006-12-12.pdf
CONTENTS December 2016,e Vol.2, No.6
Editorial:
Done't be misled by new edrugs p28
New products
Nivolumab (brand name: Opdivo) for NSC lung cancer p29-34
Benefit and harm on survival offset each other:
strict restriction on use is needed
Nivolumab not only activate immune system but also suppress immunity.
- It suppresses the function of antigen presenting cells (APCs) leading to tumor progression and worsening of infection.
- It also suppresses the function of regulatory T cells leading to induction of autoimmune diseases.e
New products
Agonists (liraglutidee -an anti-diabetics) p35-42
No evidence of improving prognosis in patients with diabetes
in spite of the claim of esuperioritye to placebo:
Not recommended
Columne
Why methods assessing anti-diabetic agents favor industry
Why should we (Japanese) pay more than 230 billion yen (2 billion dollars)
for these agents that have only the same benefit as placebos?
See also archives.
Comments and questions are welcome.
Rokuro
Professor Rokuro Hama
Japan
"HAMA, Rokuro " <gec00724@nifty.com>